FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080598808> ?p ?o ?g. }

• W2080598808 endingPage "217" @default.
• W2080598808 startingPage "217" @default.
• W2080598808 abstract "Article1 February 1964Multiple MyelomaStudies of Mouse Plasma Cell Tumor and Human Myeloma Responsiveness to Cyclophosphamide (Cytoxan)DONALD R. KORST, M.D., F.A.C.P., EUGENE P. FRENKEL, M.D., JOHN C. NIXON, M.D.DONALD R. KORST, M.D., F.A.C.P.Search for more papers by this author, EUGENE P. FRENKEL, M.D.Search for more papers by this author, JOHN C. NIXON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-60-2-217 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMultiple myeloma, a neoplasm of plasma cell origin represents a difficult therapeutic problem. Preliminary clinical trials with a new alkylating agent cyclophosphamide*(1) suggested that palliative responses in human multiple myeloma could be obtained. Investigations of myeloma have been limited by the lack of a suitable animal prototype; however, in 1957, Potter, Fahey, and Pilgrim (2) observed a plasma cell tumor in the iliocecum of C3H mice and successfully transferred the tumor subcutaneously through many generations. The tumor in mice produces bone marrow, liver, and spleen plasma cell invasion. Changes in the serum proteins are similar to the human disease....References1. KORSTJOHNSONFRENKELCHALLENER DRFDEPWL: Preliminary evaluation of the effect of cyclophosphamide on the course of human neoplasm. Cancer Chemother. Rep. 7: 1, 1960. Google Scholar2. POTTERFAHEYPILGRIM MJLHI: Abnormal serum protein and bone destruction in transmissible mouse plasma cell neoplasm (multiple myeloma). Proc. Soc. Exp. Biol. Med. 94: 327, 1957. CrossrefMedlineGoogle Scholar3. COBAUKORST CDDR: Alterations of gamma globulin with plasma cell neoplasm in mice. Proc. Soc. Exp. Biol. Med. 101: 356, 1959. CrossrefMedlineGoogle Scholar4. FRENKELKORSTRACCUGLIA EPDRG: Effects of heterologous transplantation of a mouse plasmacytoma. I. Runting syndrome secondary to malignant tumors. J. Lab. Clin. Med. 59: 81, 1962. MedlineGoogle Scholar5. WALDENSTRÖM J: Abnormal proteins in myeloma, in Advances in Internal Medicine, Vol. 5 Year Book Publishers, Inc., Chicago, 1952, p. 398. Google Scholar6. WALL RL: The use of serum protein electrophoresis in clinical medicine. Arch. Intern. Med. (Chicago) 102: 618, 1958. CrossrefGoogle Scholar7. ADAMSALLINGLAWRENCE WSELJS: Multiple myeloma. It's clinical and laboratory diagnosis with emphasis on electrophoretic abnormalities. Amer. J. Med. 6: 141, 1949. CrossrefMedlineGoogle Scholar8. SNAPPERTURNERMOSCOVITY ILBHL: Multiple Myeloma, Grune and Stratton, Inc., New York, 1953. Google Scholar9. CARSONACKERMANMALTBY CPLVJD: Plasma cell myeloma: a clinical, pathologic, and roentgen review of 90 cases. Amer. J. Clin. Path. 25: 849, 1955. CrossrefMedlineGoogle Scholar10. BAYRDHECK EDFJ: Multiple myeloma: a review of 83 proven cases. JAMA 133: 147, 1947. CrossrefMedlineGoogle Scholar11. NATHANSFAHEYPOTTER DJLM: The formation of myeloma protein by a mouse plasma cell tumor. J. Exp. Med. 108: 121, 1958. CrossrefMedlineGoogle Scholar12. HENSONLEADERGORHAM JBRWJR: Hypergammaglobulinemia in mink. Proc. Soc. Exp. Biol. Med. 107: 919, 1961. CrossrefMedlineGoogle Scholar13. RUNDLESDILLONDILLON RWMLES: Multiple myeloma. III. Effect of urethane therapy of plasma cell growth, abnormal serum, protein components, and Bence Jones proteinuria. J. Clin. Invest. 29: 1243, 1950. CrossrefMedlineGoogle Scholar14. THIERY JP: Microcinematographic contributions to study of plasma cells, in Ciba Foundation Symposium on Cellular Aspects of Immunity , edited by WOLSTENHOLME, G. E. W., and O'CONNOR, C. M., Little, Brown and Company, Boston, 1961, p. 59. (See also EDITORIAL, JAMA 179: 285, 1962.) Google Scholar15. LANE SL: Plasmocytoma of the mandible. Oral Surg. 5: 434, 1952. CrossrefMedlineGoogle Scholar16. LANE SL: Personnel communication: March 29, 1962. Google Scholar17. MILLERBROWNMILLEREITELMAN GLCEEEES: An electrophoretic study on the origin of the abnormal plasma proteins in multiple myeloma. Cancer Res. 12: 716, 1952. MedlineGoogle Scholar18. FAGRAEUS A: Antibody formation in relation to the development of plasma cells. Acta Med. Scand. Supp. 204: 1, 1948. Google Scholar19. WHITE RG: Observations on the formation and nature of Russell bodies. Brit. J. Exp. Path. 35: 365, 1954. MedlineGoogle Scholar20. VAZQUEZ JJ: Immunocytochemical study of plasma cells in multiple myeloma. J. Lab. Clin. Med. 51: 271, 1958. MedlineGoogle Scholar21. TRUAXBRAYPERRY WEJJE: A method for demonstrating probable synthesis of protein by bone marrow cells. J. Lab. Clin. Med. 17: 54, 1961. Google Scholar22. FAHEY JL: Comparison of serum myeloma proteins in mouse and man (abstract). Proc. Amer. Ass. Cancer Res. 3: 223, 1961. Google Scholar23. ASKONAS BA: A study on globulin formation by plasma-cell neoplasm (5563). Biochem. J. 79: 33, 1961. CrossrefMedlineGoogle Scholar24. DALTONPOTTERMERWIN AJMRM: Some ultrastructural characteristics of a series of primary and transplanted plasma-cell tumors of the mouse. J. Nat. Cancer Inst. 26: 1221, 1961. MedlineGoogle Scholar25. LANE M: Preliminary report of animal studies with Cytoxan (cyclophosphamide). Cancer Chemother. Rep. 3: 1, 1959. Google Scholar26. LANE M: Some effects of cyclophosphamide (Cytoxan) on normal mice and mice with L1210 leukemia. J. Nat. Cancer Inst. 23: 1347, 1959. MedlineGoogle Scholar27. POTTERLOW MLW: Studies of a plasma cell neoplasm of the mouse. J. Nat. Cancer Inst. 18: 413, 1957. MedlineGoogle Scholar28. KORSTFRENKELJOHNSONCOBAUKNORPP DREPFDCDCT: Experimental studies of the biologic and tumorigenic behavior of cyclophosphamide. Proc. VIII Int. Cong. Hematology, Tokyo, Japan, September, 1960. Google Scholar29. FOLEYFRIENDMANDROLET GEOMBP: Studies on the mechanism of action of Cytoxan. Evidence of activation in vivo and in vitro. Cancer Res. 21: 57, 1961. MedlineGoogle Scholar30. GROSSLAMBERS RK: Erste Erfahrungen in der Behandlung maligner Tumoren mit einen neuen N-lost-phosphamid-ester. Deutsch. Med. Wschr. 83: 458, 1958. CrossrefMedlineGoogle Scholar31. FAYECHAPMANWILLETTADAMS LVCGFMWS: Cyclophosphamide: a preliminary study of a new alkylating agent. Cancer Chemother. Rep. 6: 39, 1960. MedlineGoogle Scholar32. CORONBOALPERT VLK: Cancer chemotherapy with cyclophosphamide (abstract). Clin. Res. 8: 250, 1960. Google Scholar33. BERGSAGELLEVIN DEWC: A prelusive clinical trial of cyclophosphamide. Cancer Chemother. Rep. 8: 120, 1960. MedlineGoogle Scholar34. MATTHIASMISIEWICZSCOTT JQJJRB: Cyclosphosphamide in Hodgkin's disease and related disorders. Brit. Med. J. 1: 1837, 1960. CrossrefMedlineGoogle Scholar35. WALLCONRAD RLFG: Cyclophosphamide therapy. Arch. Intern. Med. (Chicago) 108: 178, 1961. CrossrefGoogle Scholar36. BAYRD ED: Continuous chlorambucil therapy in primary macroglobulinemia of Waldenström: report of 4 cases. Proc. Mayo Clin. 36: 135, 1961. MedlineGoogle Scholar37. GARLANDKENNEDY LHRB: Roentgen treatment of multiple myeloma. Radiology 50: 297, 1948. CrossrefMedlineGoogle Scholar38. BETHELL FH: Discussion remarks, in Proceedings of the Second Clinical ACTH Conference, Vol. 2, 1951, p. 216. Google Scholar39. ADAMSSKOOG WSWA: The management of multiple myeloma. J. Chron. Dis. 6: 446, 1957. CrossrefMedlineGoogle Scholar40. ALWALL N: Urethane and stilbamidine in multiple myeloma: a report on two cases. Lancet 2: 388, 1947. CrossrefMedlineGoogle Scholar41. HARRINGTONMOLONEY JW: Treatment of multiple myeloma with urethane. Cancer 3: 253, 1950. CrossrefGoogle Scholar42. LUTTGENSBAYRD WFED: Treatment of multiple myeloma with urethane. JAMA 147: 824, 1951. CrossrefMedlineGoogle Scholar43. OSSERMAN EF: Plasma cell myeloma. New Eng. J. Med. 261: 952, 1959. CrossrefMedlineGoogle Scholar44. ALWALL N: Urethane in multiple myeloma. Acta Med. Scand. 144: 114, 1952. CrossrefMedlineGoogle Scholar45. REINHARDMOOREBIERBAUMMOORE EHCVOSS: Radioactive phosphorus as a therapeutic agent. J. Lab. Clin. Med. 31: 107, 1946. MedlineGoogle Scholar46. LAWRENCEWASSERMAN JHLR: Multiple myeloma: study of 24 patients treated with radioactive isotopes (P32 and Sr89). Ann. Intern. Med. 33: 41, 1950. LinkGoogle Scholar47. LINDGRENBERGSTROMWIHMAN EIG: The treatment of multiple myelomata with radioactive phosphorus. Acta Radiol. (Stockholm) 36: 49, 1951. CrossrefMedlineGoogle Scholar48. KRISSBIERMANTHOMASNEWELL JPHRSFRR: Treatment of multiple myeloma with radioactive iodine and radioactive iodinated serum albumin. Radiology 65: 241, 1955. CrossrefMedlineGoogle Scholar49. ANDERSONEMERYMCALISTEROSBORN JEWJMSB: The metabolism of a therapeutic dose of 45ca in a case of multiple myeloma. Clin. Sci. 15: 267, 1956. Google Scholar50. BENEFIELHELSPERSHARP WWJRGG: Apparent control of multiple myeloma by 1-amino-cyclopentane-1-carboxylic acid (NSC-1026). Cancer Chemother. Rep. 9: 21, 1960. Google Scholar51. HAYESSPURR DMCL: The effect of 1-Aminocyclopentane-carboxylic acid (NSC-1026) on mouse plasmacytoma. Cancer Chemother. Rep. 14: 91, 1961. MedlineGoogle Scholar52. HOLLAND JF: Eastern solid tumor group: a comparative study of optimal medical care with and without azaserine in multiple myeloma. Clinical Pharmacol. Ther. 2: 22, 1961. CrossrefMedlineGoogle Scholar53. BAYRDHALL EDBE: Unusual remission after radiophosphorus therapy in a case of acute plasma cell leukemia. Blood 3: 1019, 1948. CrossrefMedlineGoogle Scholar54. BAYRD ED: Personal communication. March 23, 1962. Google Scholar55. GESCHICTERCOPELAND CFMM: Multiple myeloma. Arch. Surg. (Chicago) 16: 807, 1928. CrossrefGoogle Scholar56. ANDA L: Multiple myeloma. Acta Radiol. (Stockholm) 33: 515, 1950. CrossrefMedlineGoogle Scholar57. OSGOOD EE: The survival time of patients with plasmocytic myeloma. Cancer Chemother. Rep. 9: 1, 1960. MedlineGoogle Scholar58. FEINLEIBMACMAHON MB:. Duration of survival in multiple myeloma. J. Nat. Cancer Inst. 24: 1259, 1960. MedlineGoogle Scholar59. KENNYMALONEY JJWC: Long term survival in multiple myeloma. Ann. Intern. Med. 45: 950, 1956. LinkGoogle Scholar60. OWENPITNEYO'DEA JAWRJF: Myeloma serum electrophoretic patterns in conditions other than myelomatosis. J. Clin. Path. 12: 344, 1959. CrossrefMedlineGoogle Scholar61. KYLEBAYRD RAED: Primary systemic amyloidosis and myeloma. Arch Intern. Med. (Chicago) 107: 344, 1961. CrossrefMedlineGoogle Scholar62. WALDENSTRÖM J: Disturbances of gamma globulin synthesis (abstract). Ann. Intern. Med. 56: 695, 1962. LinkGoogle Scholar63. BAYRDHECK EFJ: Myeloma, a review of 469 cases. Proc. VI Congr. European Soc. Hematology, Copenhagen, Basel. S. Karger, New York, 1957. Google Scholar64. MASS RE: A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother. Rep. 16: 257, 1962. MedlineGoogle Scholar65. LIEBLINGGRIZZLEHAMMACKRUNDLES MEJWRW: Comparison of chlorambucil and prednisone with urethan and prednisone regimens in the treatment of multiple myeloma. Ibid., p. 253. Google Scholar66. BERGSAGEL DE: Phase II trials of Mitomycin C, AB-100, NSC-1026, L-Sarcolysin, and Meta-Sarcolysin, in the treatment of multiple myeloma. Ibid., p. 261. Google Scholar67. BERGSAGELSPRAGUEROSS DECCSW: Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. I. Plan of study. Cancer Chemother. Rep. 21: 69, 1962. MedlineGoogle Scholar68. BERGSAGELROSSDAVIS DESWP: Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. II. Mitomycin C (NSC-26980). Ibid., p. 75. Google Scholar69. BROWNBERGSAGELLEVIN CLDEWC: Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. III. AB-100 (NSC-37095). Ibid., p. 81. Google Scholar70. BERGSAGELSPRAGUEAUSTINGRIFFITH DECCCKM: Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Ibid., p. 87. Google Scholar71. BERGSAGELROSSBAKER DESWDT: Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. V. 1-Aminocyclopentanecarboxylic acid (NSC-1026). Ibid., p. 101. Google Scholar72. AUSTINBERGSAGELSPRAGUE CDECC: Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. VI. Meta-sarcolysin. Ibid., p. 107. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DONALD R. KORST, M.D., F.A.C.P.; EUGENE P. FRENKEL, M.D.; JOHN C. NIXON, M.D.Affiliations: Ann Arbor, MichiganFrom the Department of Hematology and Cancer Chemotherapy of St. Joseph Mercy Hospital, and the Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, Michigan.This is the Preliminary Report presented at the Forty-third Annual Meeting of the American College of Physicians, Philadelphia, Pennsylvania, April, 1962.Requests for reprints should be addressed to Donald R. Korst, M.D., 326 North Ingalls Street, Ann Arbor, Michigan.*Cyclophosphamide is an ester of phosphamide and the active alkylating group of nitrogen mustard. The drug is available in Europe as Endoxan, in Canada as Protoxan and in the U. S. as Cytoxan® (Meade-Johnson and Company). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCyclophosphamide immunosuppression does not permit successful myoblast allotransplantation in mouseA plasma clot culture system for growing and antiproliferative drug sensitivity testing of myeloma stem cellsLiteraturverzeichnisParaproteinämische HämoblastosenMelphalan and prednisone: An effective combination for the treatment of multiple myelomaSerum ribonuclease in multiple myelomaMonoclonal gammopathy with hyperlipidemiaCyclophosphamideDie therapie der ParaproteinämienZur Lebenserwartung unbehandelter und behandelter PlasmozytomkrankerClinical and metabolic investigations of eight cases of multiple myeloma during prolonged cyclophosphamide administrationAggregation of IgG globulin in vivoScientific Methodology in Clinical Medicine III. The Evaluation of Therapeutic ResponseALVAN R. FEINSTEIN, M.D. 1 February 1964Volume 60, Issue 2_Part_1Page: 217-230KeywordsCancer chemotherapyCyclophosphamideDrugsHospital medicineMultiple myelomaMyelomaPlasma cellsProteinsSpleenTumor resection ePublished: 1 December 2008 Issue Published: 1 February 1964 PDF downloadLoading ..." @default.
• W2080598808 created "2016-06-24" @default.
• W2080598808 creator A5034150489 @default.
• W2080598808 date "1964-02-01" @default.
• W2080598808 modified "2023-10-18" @default.
• W2080598808 title "Multiple Myeloma" @default.
• W2080598808 cites W1483724478 @default.
• W2080598808 cites W1497017054 @default.
• W2080598808 cites W1499030574 @default.
• W2080598808 cites W1531968409 @default.
• W2080598808 cites W1542909981 @default.
• W2080598808 cites W1551892274 @default.
• W2080598808 cites W1836727606 @default.
• W2080598808 cites W1846228332 @default.
• W2080598808 cites W1970868526 @default.
• W2080598808 cites W1972761420 @default.
• W2080598808 cites W1973049884 @default.
• W2080598808 cites W1983253084 @default.
• W2080598808 cites W1989881693 @default.
• W2080598808 cites W1991833056 @default.
• W2080598808 cites W1998465382 @default.
• W2080598808 cites W2006253972 @default.
• W2080598808 cites W2009016132 @default.
• W2080598808 cites W2038428540 @default.
• W2080598808 cites W2052557104 @default.
• W2080598808 cites W2056676047 @default.
• W2080598808 cites W2067223826 @default.
• W2080598808 cites W2085303761 @default.
• W2080598808 cites W2095418876 @default.
• W2080598808 cites W2109268088 @default.
• W2080598808 cites W2112561591 @default.
• W2080598808 cites W2118389210 @default.
• W2080598808 cites W2313328407 @default.
• W2080598808 cites W2323026436 @default.
• W2080598808 cites W2330330898 @default.
• W2080598808 cites W2335826340 @default.
• W2080598808 cites W2368951300 @default.
• W2080598808 cites W2401332591 @default.
• W2080598808 cites W2408864253 @default.
• W2080598808 cites W2412763788 @default.
• W2080598808 cites W2412771637 @default.
• W2080598808 cites W2413468970 @default.
• W2080598808 cites W2413837151 @default.
• W2080598808 cites W2415545195 @default.
• W2080598808 cites W2417420806 @default.
• W2080598808 cites W2418006527 @default.
• W2080598808 cites W2421953982 @default.
• W2080598808 cites W2474055208 @default.
• W2080598808 cites W2475155259 @default.
• W2080598808 cites W68977331 @default.
• W2080598808 doi "https://doi.org/10.7326/0003-4819-60-2-217" @default.
• W2080598808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14114442" @default.
• W2080598808 hasPublicationYear "1964" @default.
• W2080598808 type Work @default.
• W2080598808 sameAs 2080598808 @default.
• W2080598808 citedByCount "16" @default.
• W2080598808 crossrefType "journal-article" @default.
• W2080598808 hasAuthorship W2080598808A5034150489 @default.
• W2080598808 hasConcept C126322002 @default.
• W2080598808 hasConcept C2776364478 @default.
• W2080598808 hasConcept C71924100 @default.
• W2080598808 hasConceptScore W2080598808C126322002 @default.
• W2080598808 hasConceptScore W2080598808C2776364478 @default.
• W2080598808 hasConceptScore W2080598808C71924100 @default.
• W2080598808 hasIssue "2_Part_1" @default.
• W2080598808 hasLocation W20805988081 @default.
• W2080598808 hasLocation W20805988082 @default.
• W2080598808 hasOpenAccess W2080598808 @default.
• W2080598808 hasPrimaryLocation W20805988081 @default.
• W2080598808 hasRelatedWork W1995515455 @default.
• W2080598808 hasRelatedWork W2047345996 @default.
• W2080598808 hasRelatedWork W2080531066 @default.
• W2080598808 hasRelatedWork W2315300816 @default.
• W2080598808 hasRelatedWork W2360955809 @default.
• W2080598808 hasRelatedWork W2404733967 @default.
• W2080598808 hasRelatedWork W2435227317 @default.
• W2080598808 hasRelatedWork W2748952813 @default.
• W2080598808 hasRelatedWork W2899084033 @default.
• W2080598808 hasRelatedWork W3032375762 @default.
• W2080598808 hasVolume "60" @default.
• W2080598808 isParatext "false" @default.
• W2080598808 isRetracted "false" @default.
• W2080598808 magId "2080598808" @default.
• W2080598808 workType "article" @default.